<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2016-6-101-105</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НОВОСТИ КОЛОПРОКТОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEWS OF COLOPROCTOLOGY</subject></subj-group></article-categories><title-group><article-title>Внекишечные проявления воспалительных заболеваний кишечника: артропатии и артриты</article-title><trans-title-group xml:lang="en"><trans-title>Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Садыгова</surname><given-names>Гюлюстан Гамид</given-names></name><name name-style="western" xml:lang="en"><surname>Sadygova</surname><given-names>Gulustan Hamid</given-names></name></name-alternatives><email xlink:type="simple">doctorabu@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Азербайджанский государственный институт усовершенствования врачей им. А. Алиева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Azerbaijan State Advanced Training Institute for Doctors named after A.Aliyev</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>08</month><year>2018</year></pub-date><volume>26</volume><issue>6</issue><fpage>101</fpage><lpage>105</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Садыгова Г.Г., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Садыгова Г.Г.</copyright-holder><copyright-holder xml:lang="en">Sadygova G.H.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/100">https://www.gastro-j.ru/jour/article/view/100</self-uri><abstract><p>Цель обзора. Представить основные внекишечные проявления воспалительных заболеваний кишечника (ВЗК) и основные подходы к ведению пациентов с язвенным колитом и болезнью Крона, у которых в качестве внекишечного проявления выступают артропатии и артриты. Основные положения. Язвенный колит и болезнь Крона - группа заболеваний неизвестной этиологии, объединенных под общим термином воспалительные заболевания кишечника. ВЗК - это патологии с социальной значимостью, которую определяют преобладание заболеваний среди лиц молодого трудоспособного возраста и склонность патологического процесса к хронизации, что приводит к ухудшению качества жизни больных и формированию высокой потребности в стационарном лечении. Язвенный колит и болезнь Крона имеют многообразную клиническую картину с различными кишечными осложнениями и внекишечными проявлениями. В данной статье приводятся результаты собственных исследований, соответствующие мировым литературным данным и положениям первого Европейского консенсуса по внекишечным проявлениям при ВЗК. Представленный материал показывает тяжесть и агрессивность течения ВЗКассоциированных артропатий, их вклад в ухудшение качества жизни пациента и риск потери трудоспособности, в связи с чем ранняя диагностика, своевременная, адекватная медикаментозная коррекция с мультидисциплинарным подходом в разрешении данной проблемы являются не просто актуальным направлением, но и требованием мирового медицинского сообщества по вопросам терапии и реабилитации больных с ВЗК. Заключение. Подробный анализ внекишечных проявлений ВЗК, в частности ВЗК-артропатий и артритов, расширяет возможности своевременной диагностики и адекватной медикаментозной терапии для снижения риска потери трудоспособности и для улучшения качества жизни пациентов с ВЗК.</p></abstract><trans-abstract xml:lang="en"><p>Aim of review. To present major extraintestinal manifestations of inflammatory bowel diseases (IBD) and basic  approaches  to  management  of  patients  with ulcerative colitis and Crohn's disease having arthropathies and arthrites as extraintestinal manifestations. Summary. Ulcerative colitis and Crohn's disease represent the group of the diseases with unknown etiology encompassed by the term «inflammatory bowel diseases». IBDs are diseases with high social impact due to predominance of young patients of working-age and tendency to chronization of pathological process that leads to deterioration of life of patients and high demand in hospital stay. Ulcerative colitis and Crohn's disease have diverse clinical presentation with various intestinal complications and extraintestinal manifestations. The results of original studies corresponding to world literary data and data of the First European evidencebased consensus on extra-intestinal manifestations in inflammatory bowel disease are presented in this article. Presented data indicates severity and aggressive course of the IBD-associated arthropathies, their contribution to quality of life deterioration and risk of disability that requires diagnostics, timely and adequate pharmacological treatment with multidisciplinary approach. Resolution of this issue is not only an actual trend, but a demand of worldwide medical community for treatment and rehabilitation IBD patients as well. Conclusion. Meditate analysis of extraintestinal IBD manifestations, in particular IBD-associated arthropathy and arthritis, expands potential of time the diagnosis and adequate drug treatment to decrease disability risk and to improve quality of life of IBD patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>воспалительные заболевания кишечника</kwd><kwd>язвенный колит</kwd><kwd>болезнь Крона</kwd><kwd>внеки-шечные проявления</kwd><kwd>артропатии</kwd><kwd>артриты</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bernstein C. N., Blanchard J. F., Rawsthorne P., et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96:1116-22.</mixed-citation><mixed-citation xml:lang="en">Bernstein C. N., Blanchard J. F., Rawsthorne P., et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96:1116-22.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bourikas L. A., Papadakis K. A. Musculoskeletal manifestations of inflammatory bowel disease. Inflam Bowel Dis 2009; 15:1915-24.</mixed-citation><mixed-citation xml:lang="en">Bourikas L. A., Papadakis K. A. Musculoskeletal manifestations of inflammatory bowel disease. Inflam Bowel Dis 2009; 15:1915-24.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">El Miedany Y., Youssef S., Ahmed I., et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101:311-7.</mixed-citation><mixed-citation xml:lang="en">El Miedany Y., Youssef S., Ahmed I., et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101:311-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraz M. B., Tugwell P., Goldsmith C. H., et al. Metaanalysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17:1482-6.</mixed-citation><mixed-citation xml:lang="en">Ferraz M. B., Tugwell P., Goldsmith C. H., et al. Metaanalysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17:1482-6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fornaciari G., Salvarani C., Beltrami M., et al. Muscoloskeletal manifestations in inflammatory bowel disease. Canadian J Gastroenterol 2001; 15:399-403.</mixed-citation><mixed-citation xml:lang="en">Fornaciari G., Salvarani C., Beltrami M., et al. Muscoloskeletal manifestations in inflammatory bowel disease. Canadian J Gastroenterol 2001; 15:399-403.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63:1664-9.</mixed-citation><mixed-citation xml:lang="en">Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63:1664-9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, openlabel, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002; 97:2688-90.</mixed-citation><mixed-citation xml:lang="en">Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, openlabel, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 2002; 97:2688-90.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hindorf U., Johansson M., Eriksson A., et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29:654-61.</mixed-citation><mixed-citation xml:lang="en">Hindorf U., Johansson M., Eriksson A., et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29:654-61.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Leclerc-Jacob S., Lux G., Rat A. C., et al. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014; 39:957-62.</mixed-citation><mixed-citation xml:lang="en">Leclerc-Jacob S., Lux G., Rat A. C., et al. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014; 39:957-62.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Marzo-Ortega H., McGonagle D., O’Connor P., et al.Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62:74-6.</mixed-citation><mixed-citation xml:lang="en">Marzo-Ortega H., McGonagle D., O’Connor P., et al.Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62:74-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mendoza J. L., Lana R., Taxonera C., et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc) 2005; 125:297-300.</mixed-citation><mixed-citation xml:lang="en">Mendoza J. L., Lana R., Taxonera C., et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc) 2005; 125:297-300.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Orchard T. R., Holt H., Bradbury L., et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn’s disease. Aliment Pharmacol Ther 2009; 29:193-7.</mixed-citation><mixed-citation xml:lang="en">Orchard T. R., Holt H., Bradbury L., et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn’s disease. Aliment Pharmacol Ther 2009; 29:193-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Palm O., Moum B., Ongre A., et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29:511-5.</mixed-citation><mixed-citation xml:lang="en">Palm O., Moum B., Ongre A., et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29:511-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Poddubnyy D., Rudwaleit M., Haibel H., et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:1369-74.</mixed-citation><mixed-citation xml:lang="en">Poddubnyy D., Rudwaleit M., Haibel H., et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:1369-74.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rodríguez-Reyna T.S., Martínez-Reyes C., YamamotoFurusho J. K. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol 2009; 15:5517-24.</mixed-citation><mixed-citation xml:lang="en">Rodríguez-Reyna T.S., Martínez-Reyes C., YamamotoFurusho J. K. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol 2009; 15:5517-24.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009; 15:2449-55.</mixed-citation><mixed-citation xml:lang="en">Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009; 15:2449-55.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Salvarani C., Vlachonikolis I. G., van der Heijde D. M., et al. Musculoskeletal manifestations in a populationbased cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36:1307-13.</mixed-citation><mixed-citation xml:lang="en">Salvarani C., Vlachonikolis I. G., van der Heijde D. M., et al. Musculoskeletal manifestations in a populationbased cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36:1307-13.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sandborn W. J., Stenson W. F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4:203-11.</mixed-citation><mixed-citation xml:lang="en">Sandborn W. J., Stenson W. F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4:203-11.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Steer S., Jones H., Hibbert J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003; 30:518-22.</mixed-citation><mixed-citation xml:lang="en">Steer S., Jones H., Hibbert J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003; 30:518-22.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">The first european evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease. J Crohn’s and Colitis 2016; 10(3):239-25.</mixed-citation><mixed-citation xml:lang="en">The first european evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease. J Crohn’s and Colitis 2016; 10(3):239-25.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Bosch F., Kruithof E., de Vos M., et al.</mixed-citation><mixed-citation xml:lang="en">Van den Bosch F., Kruithof E., de Vos M., et al.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356:1821-2.</mixed-citation><mixed-citation xml:lang="en">Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356:1821-2.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Vavricka S. R., Brun L., Ballabeni P., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106:110-9.</mixed-citation><mixed-citation xml:lang="en">Vavricka S. R., Brun L., Ballabeni P., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106:110-9.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Vavricka S. R., Rogler G., Gantenbein C., et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 2015.</mixed-citation><mixed-citation xml:lang="en">Vavricka S. R., Rogler G., Gantenbein C., et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 2015.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Veloso F. T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34.</mixed-citation><mixed-citation xml:lang="en">Veloso F. T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vind I., Riis L., Jess T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-82.</mixed-citation><mixed-citation xml:lang="en">Vind I., Riis L., Jess T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-82.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Yüksel I., Ataseven H., Başar O., et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci 2011; 56:183-7.</mixed-citation><mixed-citation xml:lang="en">Yüksel I., Ataseven H., Başar O., et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci 2011; 56:183-7.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zochling J., van der Heijde D., Dougados M., et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65:423-32.</mixed-citation><mixed-citation xml:lang="en">Zochling J., van der Heijde D., Dougados M., et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65:423-32.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
